Heparosan细胞入胞途径及其胞内分布  

Endocytosis pathway and intracellular distribution of heparosan

作　　者：彭换换 李颖[1] 袁嘉怿 陈荆晓[1] 陈敬华[1] 

机构地区：[1]江南大学药学院,江苏无锡214122

出　　处：《药学学报》2017年第3期474-480,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(51303068;21574059;21306066);安徽大学现代生物制造协同创新中心开放课题资助项目(BM2015008)

摘　　要：本文对肝素前体(heparosan)的细胞摄取途径及其进入细胞后的分布情况进行了研究。通过胞吞途径抑制及细胞探针定位实验发现,MCF-7肿瘤细胞较COS7正常细胞对heparosan的摄取效率更高,具有选择性。Heparosan在MCF-7肿瘤细胞和COS7正常细胞中的内吞过程均为能量依赖。Heparosan主要通过小窝蛋白和巨胞饮介导的内吞进入MCF-7肿瘤细胞,并且主要分布于溶酶体中。In this study, the endocytosis pathway of heparosan and its intracellular distribution were investigated in MCF-7 tumor cells and COS7 normal cells. The endocytosis inhibition and cellular probe location experiments showed that MCF-7 tumor cells took heparosan more efficiently and selectively than COS7 cells. The cellular uptake of heparosan was energy-dependent in both MCF-7 tumor cells and COS7 normal cells. Moreover, the major endocytosis pathway of heparosan into MCF-7 tumor cells was caveolin-mediated endocytosis and macropinocytosis. The internalized heparosan was mainly located in lysosomes of the cells.

关 键 词：肝素前体 入胞途径 胞内分布 药物载体 

分 类 号：R943[医药卫生—药剂学]